Managing blood disorders during the Covid-19 pandemic: current pharmacological insights

Karunakaran, Parathan; Nampoothiri, Ram Vasudevan; Sahu, Kamal Kant

doi:10.1080/17512433.2020.1841633

Cited by 3 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with acute myeloid leukemia (AML), the standard 7 + 3 combination regimen of cytarabine for 7 days along with short infusions of anthracycline for 3 days is recommended [ 99 ]. High doses of cytarabine can still be administered post-remission [ 100 ]. Patients with acute lymphocytic leukemia (ALL) should be treated conscientiously with high-dose steroids only during the post-induction phase, as steroids are associated with viral shedding and mortality.…”

Section: How To Manage Blood Disordersmentioning

confidence: 99%

“…Philadelphia-chromosome-positive ALL patients should be given a tyrosine kinase inhibitor [ 101 ]. In patients with chronic myeloid leukemia (CML), extreme caution should be taken during the first 3 months of treatment with tyrosine kinase inhibitors as they may induce therapy-related cytopenia [ 100 ]. However, tyrosine kinase inhibitors (TKI) plus steroids have been used successfully to manage patients with both Philadelphia chrompsome-positive ALL and CML in Italy [ 102 ].…”

Section: How To Manage Blood Disordersmentioning

confidence: 99%

“…Strict leukocyte count control with hydroxyurea may also decrease the risk of thrombosis. In patients with indolent lymphomas, Rituximab may be considered a single agent [ 100 ]. In patients with CLL, Ibrutinib has been proven to be safe and may have the added benefit of preserving pulmonary function in those with severe COVID-19 [ 104 , 105 ].…”

Section: How To Manage Blood Disordersmentioning

confidence: 99%

“…In patients with CLL, Ibrutinib has been proven to be safe and may have the added benefit of preserving pulmonary function in those with severe COVID-19 [ 104 , 105 ]. ABVD (adriamycin, bleomycin sulfate, vinblastine sulfate, and dacarbazine) is the preferred regimen for Hodgkin’s lymphoma [ 100 , 106 ]. Table 4 summarizes the therapeutics of blood disorders in patients with COVID-19.…”

Section: How To Manage Blood Disordersmentioning

confidence: 99%

See 3 more Smart Citations

A Review of Hematological Complications and Treatment in COVID-19

Yazdani,

Abdi,

Velpuri

et al. 2023

Hematology Reports

View full text Add to dashboard Cite

COVID-19, caused by SARS-CoV-2, and its variants have spread rapidly across the globe in the past few years, resulting in millions of deaths worldwide. Hematological diseases and complications associated with COVID-19 severely impact the mortality and morbidity rates of patients; therefore, there is a need for oversight on what pharmaceutical therapies are prescribed to hematologically at-risk patients. Thrombocytopenia, hemoglobinemia, leukopenia, and leukocytosis are all seen at increased rates in patients infected with COVID-19 and become more prominent in patients with severe COVID-19. Further, COVID-19 therapeutics may be associated with hematological complications, and this became more important in immunocompromised patients with hematological conditions as they are at higher risk of hematological complications after treatment. Thus, it is important to understand and treat COVID-19 patients with underlying hematological conditions with caution. Hematological changes during COVID-19 infection and treatment are important because they may serve as biomarkers as well as to evaluate the treatment response, which will help in changing treatment strategies. In this literature review, we discuss the hematological complications associated with COVID-19, the mechanisms, treatment groups, and adverse effects of commonly used COVID-19 therapies, followed by the hematological adverse events that could arise due to therapeutic agents used in COVID-19.

show abstract

Section: How To Manage Blood Disordersmentioning

confidence: 99%

Section: How To Manage Blood Disordersmentioning

confidence: 99%

Section: How To Manage Blood Disordersmentioning

confidence: 99%

Section: How To Manage Blood Disordersmentioning

confidence: 99%

See 2 more Smart Citations

A Review of Hematological Complications and Treatment in COVID-19

Yazdani,

Abdi,

Velpuri

et al. 2023

Hematology Reports

View full text Add to dashboard Cite

show abstract

“…The COVID-19 pandemic has proven to be devastating for all the countries. 1 The treatment has been mostly limited to symptomatic and supportive care. Various drugs have been repurposed and tried for their potential role in treatment of COVID-19.…”

mentioning

confidence: 99%

Methemoglobinemia in COVID-19

Sahu

Mishra

2021

The American Journal of the Medical Sciences

Self Cite

View full text Add to dashboard Cite

Clinical features and disease severity in an Iranian population of inpatients with COVID-19

Nabavi

Javidarabshahi

Allahyari

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) can present with a variety of symptoms. Severity of the disease may be associated with several factors. Here, we review clinical features of COVID-19 inpatients with different severities. This cross-sectional study was performed in Imam Reza hospital, Mashhad, Iran, during February–April 2020. COVID-19 patients with typical computed tomography (CT) patterns and/or positive reverse-transcriptase polymerase chain reaction (RT-PCR) were included. The patients were classified into three groups of moderate, severe, and critical based on disease severity. Demographic, clinical, laboratory, and radiologic findings were collected and compared. P < 0.05 was considered statistically significant. Overall, 200 patients with mean age of 69.75 ± 6.39 years, of whom 82 (41%) were female were studied. Disease was severe/critical in the majority of patients (167, 83.5%). Disease severity was significantly associated with age, malignant comorbidities, dyspnea, nausea/vomiting, confusion, respiratory rate, pulse rate, O2 saturation, extent of CT involvement, serum C-reactive protein (CRP), pH, pO2, and aspartate transaminase (P < 0.05). Moreover, complications including shock, coagulopathy, acidosis, sepsis, acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admission, and intubation were significantly higher in patients with higher severities (P < 0.05). O2 saturation, nausea/vomiting, and extent of lung CT involvement were independent predictors of severe/critical COVID-19 (OR 0.342, 45.93, and 25.48, respectively; P < 0.05). Our results indicate O2 saturation, nausea/vomiting, and extent of lung CT involvement as independent predictors of severe COVID-19 conditions. Serum CRP levels and pO2 were also considerably higher patients with higher severity and can be used along with other factors to predict severe disease in COVID-19 patients.

show abstract

Managing blood disorders during the Covid-19 pandemic: current pharmacological insights

Cited by 3 publications

References 14 publications

A Review of Hematological Complications and Treatment in COVID-19

A Review of Hematological Complications and Treatment in COVID-19

Methemoglobinemia in COVID-19

Clinical features and disease severity in an Iranian population of inpatients with COVID-19

Contact Info

Product

Resources

About